Bargay Lleonart, JoanSarubbo, FiorellaArrizabalaga, MariaGuerra, José MariaBorrás, JosepEl Haji, KhaoulahFlexas, MagdalenaPerales, JorgeFernández-Baca, VictoriaGallegos, CarmenRaya-Cruz, ManuelVelasco, SoniaLópez, VíctorCruz, AnaBautista-Gili, AntoniaJimenez-Marco, TeresaGirona-Llobera, EnriqueVilaplana Marz, LaiaCalonge Raventós, Laura:Tena, JuanGalan, PilarPayeras Cifre, Antonio2024-10-042024-10-042022-05-27Bargay-Lleonart J, Sarubbo F, Arrizabalaga M, Guerra JM, Borràs J, El Haji K, et al. Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial. J Clin Med. 2022 May 27;11(11):3039.2077-0383http://hdl.handle.net/20.500.13003/18033https://hdl.handle.net/20.500.12105/23509Background: The aim was to evaluate the reinforcement of the standard therapy with hyperimmune plasma (HP) in Coronavirus-19 disease (COVID-19) patients. Methods: Open-label, multicenter, randomized clinical trial performed in three hospitals in the Balearic Islands. Non-severe COVID-19 hospitalized patients with clinical time evolution equal to/less than 7 days were included, and randomized in: plasma group (PG) (n = 37), receiving 600 mL divided into two doses from convalescent plasma donor, administered on days 1 and 2 after the enrollment; and control group (CG) (n = 17). Primary outcome was the time for clinical improvement within 21 days, defined as patient achievement of categories 8, 7, and 6 in the Adaptive COVID-19 Treatment Trial scale (ACTT). The trial was terminated early due to the impossibility of recruitment due to the pandemic. Results: PG presented better scores on the ACTT scale at 7 days after HP infusion, whereas CG was needed 14 days to achieve similar results. The plasma infusion was safe. Conclusions: Despite the tendency observed in the plasma group to achieve slightly earlier better physical condition compared with the standard treatment alone. The administration of HP has been shown to be a safe therapy. No robust evidence was found to affirm a therapeutic effect of the early administration of two infusions of HP for non-severe COVID-19 infected patients. The interpretation is limited by the early termination of the trial, which resulted in a small sample size.enghttp://creativecommons.org/licenses/by/4.0/research articleAttribution 4.0 International356834271111303910.3390/jcm11113039Journal of clinical medicineopen access808847000001L2016905999